Chimerix to Report Second Quarter 2020 Financial Results and Provide an Operational Update on August 10, 2020
August 03, 2020 08:00 ET
|
Chimerix, Inc.
DURHAM, N.C., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases,...
Chimerix Appoints Allen Melemed, M.D. as Chief Medical Officer
June 22, 2020 07:00 ET
|
Chimerix, Inc.
DURHAM, N.C., June 22, 2020 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases,...
Chimerix to Present at H.C. Wainwright Virtual Fireside Chat Series
June 18, 2020 08:00 ET
|
Chimerix, Inc.
DURHAM, N.C., June 18, 2020 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases,...
Chimerix to Present at Jefferies Virtual Healthcare Conference
May 28, 2020 08:00 ET
|
Chimerix, Inc.
DURHAM, N.C., May 28, 2020 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases,...
Chimerix Reports First Quarter 2020 Financial Results and Provides Operational Update
May 07, 2020 07:00 ET
|
Chimerix, Inc.
DURHAM, N.C., May 07, 2020 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases,...
Chimerix Announces Initiation of a Phase 2/3 Study of DSTAT in Acute Lung Injury for Patients with Severe COVID-19
April 29, 2020 07:00 ET
|
Chimerix, Inc.
FDA Clearance to Proceed with Phase 2/3 Randomized, Double-Blind, Placebo Controlled Study Mechanisms of Action May Address Overactive Inflammatory Response, Including Underlying Causes of Blood...
Chimerix Receives FDA Clearance for Rolling Submission of New Drug Application for Brincidofovir as a Medical Countermeasure for Smallpox
April 28, 2020 16:30 ET
|
Chimerix, Inc.
DURHAM, N.C., April 28, 2020 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases,...
Chimerix to Present at Cowen and Company 40th Annual Health Care Conference
February 26, 2020 08:00 ET
|
Chimerix, Inc.
DURHAM, N.C., Feb. 26, 2020 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases,...
Chimerix Reports Fourth Quarter and Year End 2019 Financial Results and Provides Operational Update
February 25, 2020 07:00 ET
|
Chimerix, Inc.
- Successful DSTAT End of Phase 2 Meeting with FDA Confirms Phase 3 Readiness; First Patient Visit Expected mid-2020 in 1L AML - - Brincidofovir pre-NDA Meeting Scheduled with FDA, on Track for...
Chimerix Appoints Pratik S. Multani, M.D., to Board of Directors
February 24, 2020 08:00 ET
|
Chimerix, Inc.
DURHAM, N.C., Feb. 24, 2020 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases,...